- Home
- LRE vs ELTX Comparison
LRE vs ELTX Comparison
Compare LRE & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | ELTX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 141.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LRE | ELTX |
|---|---|---|
| Price | $1.30 | $8.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 7.9K | ★ 107.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $4.60 |
| 52 Week High | $2.97 | $12.62 |
Technical Indicators
Market Signals| Indicator | LRE | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 46.72 |
| Support Level | $1.29 | $7.89 |
| Resistance Level | $1.45 | $8.39 |
| Average True Range (ATR) | 0.07 | 0.50 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 25.60 | 36.61 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.